
- /
- Supported exchanges
- / US
- / IONS.NASDAQ
Ionis Pharmaceuticals Inc (IONS NASDAQ) stock market data APIs
Ionis Pharmaceuticals Inc Financial Data Overview
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy. It also develops products under Phase 3 clinical trials, such as Olezarsen for patients with hypertriglyceridemia (SHTG) and cardiovascular disease (CVD); Donidalorsen for patients with hereditary angioedema; and Zilganerse, a potential treatment for people with genetically confirmed Alexander disease, as well as ION582 that has completed Phase 2 clinical trial for the potential treatment of AS, a rare genetic neurological disease. In addition, the company develops Eplontersen to degrade mutant and wild-type TTR mRNA through binding to the TTR mRNA; Pelacarsen to inhibit the production of apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus; Sefaxersen to reduce the production of complement factor B and lower activation of the alternative complement pathway; and Ulefnersen to reduce the production of the fused in sarcoma, as well as other mid-stage pipeline investigational medicines. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with GSK, AstraZeneca, Novartis, and Roche, as well as with Metagenomi. The company was incorporated in 1989 and is headquartered in Carlsbad, California.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Ionis Pharmaceuticals Inc data using free add-ons & libraries
Get Ionis Pharmaceuticals Inc Fundamental Data
Ionis Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 717 M
- EBITDA: -460 854 016
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-05
- EPS/Forecast: -1.01
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Ionis Pharmaceuticals Inc News

Ionis announces Dr. Richard Geary, chief development officer, to retire; Dr. Holly Kordasiewicz to assume role in January 2026
CARLSBAD, Calif., June 12, 2025--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Richard Geary, Ph.D., executive vice president and chief development officer, will ret...


First patient dosed in pivotal Phase 3 REVEAL clinical study of ION582 in Angelman syndrome
- Completion of enrollment anticipated in 2026 - CARLSBAD, Calif., June 11, 2025--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the first participant has been dosed...

Why Is Esperion Therapeutics (ESPR) Up 28.6% Since Last Earnings Report?
It has been about a month since the last earnings report for Esperion Therapeutics (ESPR). Shares have added about 28.6% in that time frame, outperforming the S&P 500. Will the recent positive trend ...

Recursion Pharmaceuticals (RXRX) Up 5.7% Since Last Earnings Report: Can It Continue?
It has been about a month since the last earnings report for Recursion Pharmaceuticals (RXRX). Shares have added about 5.7% in that time frame, underperforming the S&P 500. Will the recent positive t...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.